SCHEMBL14770522

SCHEMBL14770522

Cc1ccc(COc2ccc(C(C)c3nc4cc(Cl)cnc4[nH]3)cc2)cc1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
MAOB P27338 5/20 0.36
MAOA P21397 3/20 0.36
ACHE P22303 1/20 0.36
FFAR1 O14842 2/20 0.36
ALOX5 P09917 1/20 0.36
ALOX5AP P20292 1/20 0.36
ALDH1A1 P00352 1/20 0.36
MAPT P10636 1/20 0.36
MAPK1 P28482 1/20 0.36
HRH3 Q9Y5N1 1/20 0.36
RXRA P19793 1/20 0.36
RXRB P28702 1/20 0.36
APP P05067 1/20 0.35
LMNA P02545 1/20 0.34
PARP10 Q53GL7 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14770524 0.91 APP (0.40) MAOBMAOAACHEFFAR1APP
SCHEMBL14770523 0.88 FFAR1 (0.36) NPC1RAB9ASMN1; SMN2MAOBMAOA
SCHEMBL12065313 0.86 FFAR1 (0.42) NPC1RAB9ASMN1; SMN2MAOBMAOA
SCHEMBL14770519 0.82 MAPK1 (0.38) ALOX5MAPK1
SCHEMBL14770521 0.82 NPC1 (0.42) NPC1RAB9ASMN1; SMN2MAOBFFAR1
SCHEMBL14770525 0.81 APP (0.42) MAOBMAOAFFAR1APP
SCHEMBL14770573 0.78 MEN1 (0.46) NPC1RAB9ASMN1; SMN2MAOBMAOA
SCHEMBL14763411 0.77 FFAR1 (0.39) MAOBMAOAFFAR1APP
SCHEMBL12065636 0.76 MLKL (0.42) NPC1RAB9ASMN1; SMN2MAOBMAOA
SCHEMBL14770515 0.76 MLKL (0.42) NPC1RAB9ASMN1; SMN2MAOBFFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096531-B2 Fused imidazole derivative TOA EIYO LTD. (JP) 2015-08-04 US disclosed
US-20130065896-A1 FUSED IMIDAZOLE DERIVATIVE TOA EIYO LTD. (JP) 2013-03-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130065896-A1 FUSED IMIDAZOLE DERIVATIVE CACNA1E, CACNA1G, CACNA1A NPC1 2440/4885RAB9A 298/4885SMN1; SMN2 1964/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.